research use only

Bezuclastinib c-Kit inhibitor

Name: Bezuclastinib
SKU: E1509
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1509

Bezuclastinib(CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V with an IC50 value of <1 μM. This compound is also an inhibitor of tyrosine kinase.

Chemical Structure

Molecular Weight: 331.37

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: E150901 DMSO]33 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.33%

99.33

Related Targets	EGFR VEGFR PDGFR FGFR c-Met Src FLT3 HER2 Bcr-Abl MEK BTK IGF-1R ALK Trk receptor Syk Axl CSF-1R c-RET FAK Mertk Tie-2 DYRK Tyro3 Ephrin receptor ROS1 Pyk2 RON DDR ACK Fer kinase
Related Products	Masitinib Amuvatinib (MP-470) OSI-930 Sitravatinib (MGCD516) ISCK03 PDGFR inhibitor 1 Elenestinib phosphate M4205（IDRX-42） Masitinib mesylate AZD3229 c-Kit Antibody [C9J3]

Chemical Information, Storage & Stability

Molecular Weight	331.37	Formula	C₁₉H₁₇N₅O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1616385-51-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Solubility

In vitro
Batch:

DMSO : 33 mg/mL (99.58 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.200mg/ml (0.60mM)	Taking the 1 mL working solution as an example, add 50 μL of 4 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.800mg/ml (2.41mM)	Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	c-kit ^[1] <1 μM c-kit D816V ^[1] <1 μM
References	[1] https://patents.google.com/patent/WO2014100620A2/en?oq=WO2014100620+A2

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06208748	Not yet recruiting	Gastrointestinal Stromal Tumors\|GIST	Sarcoma Alliance for Research through Collaboration\|Cogent Biosciences Inc.\|Dana-Farber Cancer Institute\|The Life Raft Group	March 2024	Phase 2
NCT04996875	Recruiting	Advanced Systemic Mastocytosis (AdvSM)\|SM With an Associated Hematologic Neoplasm (SM-AHN)\|Mast Cell Leukemia (MCL)\|Aggressive Systemic Mastocytosis (ASM)	Cogent Biosciences Inc.	November 9 2021	Phase 2
NCT02401815	Completed	Gastrointestinal Stromal Tumors	Cogent Biosciences Inc.\|Plexxikon	March 6 2015	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):